Consistent with our in vitro findings, tumors derived from USP22 shRNA-transfacted A549 cells grew at a much slower rate than those derived from SCR shRNA-transfected cells, as reflected in the significantly smaller tumor size (Figure 6A) and tumor weight (Figure 6B) four weeks after cell implantation. Here, USP22 is linked to neoplasm.